Compared to placebo what was the result of (40–80 mg/d, flexibly dosed) for an additional 28-week treatment period on adverse event and extrapyramidal symptoms (EPS)-related adverse events?
In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447–0.983); p=0.041).